Moderna Times

The story behind the innovative technology that led to a highly effective coronavirus vaccine

Moderna Times The Moderna coronavirus vaccine is beginning its global rollout. From humble beginnings, thanks to its revolutionary research, Moderna is now globally reputed with a value of some 40 billion Euros.
In March 2020, Swiss biotech company Moderna was confident that it could deliver a coronavirus vaccine 'in the next few months'. Now, it is rolling out a vaccine that is 94% effective, developed by utilising revolutionary RNA technology. In 2011, Stéphane Bancel became director of Moderna at a precarious time: ' either the company would go bankrupt, or it would have a lot of products to sell to market.' By 2013, the company has just 20 employees, but its unique, experimental research appealed to investors: 'the company was able to lure people who wanted to be part of this adventure ... a lot of people took huge risks', explains one early investor. Lonza chemical company, a manufacturer, was also swayed by Moderna's pioneering nature, partnering with Moderna to produce the vaccine at astonishing speed. Yet not everyone believed in Moderna - including the Swiss government, which negotiated a vaccine deal later than other nations. Israel, for example, has 'a much larger number of people vaccinated [because] they negotiated better or put more money in earlier', says editor in chief of the Swiss Medical Journal.

This site uses cookies. By continuing to use this site you are agreeing to our use of cookies. For more info see our Cookies Policy